Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2023-05-30 Regulatory Filings
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Vivo Bio Tech Limited has submitted with the exchange the Audited Standalone & Consolidated Financial Statements of the Company for the fourth quarter and year ended March 31, 2023.
Regulatory Filings
2023-05-30 English
Vivo Bio Tech Limited has submitted with the exchange the Outcome of Board meeting for the item transacted for approval of Audited Standalone & Consolidated Financial Statements of the ....
Regulatory Filings
2023-05-30 English
VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve Audited Standalone and Consolidated ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the date of a Board Meeting scheduled to consider and approve audited financial results for the fiscal year ended March 31, 2023. It references Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to board meeting disclosures. The document does not contain any financial data or results itself, only an announcement of the meeting date and agenda. The length is only 1753 characters, indicating it is a brief announcement rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about a board meeting and upcoming financial results, not the results or report themselves.
2023-05-18 English
Vivo Bio Tech Limited has submitted with the Exchange Annual Secretarial Compliance Report for the year ended March 31, 2023.
Regulatory Filings
2023-05-16 English
Vivo Bio Tech Limited has submitted with the exchange the certificate issued by Company Secretary in Practice under Regulation 40(9) read with Regulation 40 (10) of the SEBI (Listing Obligations ....
Regulatory Filings
2023-04-26 English
Vivo Bio Tech Limited has submitted with the exchange the Compliance Certificate for the year ended March 31, 2023 in complinace with Regulation 7(3) of SEBI (Listing Obligations and Disclosure ....
Regulatory Filings
2023-04-18 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.